



Restoring Health

Kora Healthcare

Swords Business Campus,

Balheary Road, Swords,

Co. Dublin, Ireland

T + 353 (0)1 890 0406

T 1800 42 62 82

(Freephone ROI)

F + 353 (0)1 890 3016

United Kingdom

T (UK) 0845 303 8631

F (UK) 0845 303 8632

Canada

Vancouver

V6Z 2E6

E info@korahealthcare.com

www.korahealthcare.com

07 February 2025

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

Magnesium Kora Healthcare 4 mmol (97 mg) tablets (Magnesium citrate nonahydrate): Supply of Magmedi 97 mg tablets

Dear Healthcare professional,

Summary: Kora Healthcare is supplying packs of Magmedi 97 mg tablets to ensure patient access to Magnesium Kora Healthcare 4 mmol (97mg) tablets

To ensure continuity in supply, Kora Healthcare has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to supply Magmedi 97 mg tablets (batch number 23JQ213; batch size – 2014), which is expected to be on the UK market from end 28 Feb 2025 to 30 Apr 2025.

Please note the following:

- Magnesium Kora Healthcare 4mmol (97mg) Tablets and Magmedi 97 mg tablets are the same product. The product is manufactured and released under the same conditions.
- Magmedi is a multilingual pack for Ireland, Belgium and the Netherlands and contains information in the following languages: English, German, French and Dutch.
- Magnesium Kora Healthcare 4mmol (97mg) Tablets is a UK only pack and contains information in English only.
- This product is considered licensed in the UK
- Please ensure the UK Summary of Product Characteristics (<https://tinyurl.com/MgKHCUK>) and Patient Information Leaflet (<https://tinyurl.com/MgKHCPIL>) are followed. The Patient Information Leaflet can be found within the pack.

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to patients. Please remove this letter before sharing with the patient and ensure that only the attached patient letter is provided to them.

Call for reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme.

Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason.



- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼
-

You can report via:

- the [Yellow Card website](#)
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals


Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, timing onset, treatment dates, and product brand name.

Company contact point

If you have any questions about this letter or require more information about Magmedi 97 mg tablets, please contact Kora Healthcare's Medical Information at +353-1-8900406 or medinfo@korahealthcare.com

Yours faithfully,



Niall Jones (Feb 7, 2025 15:10 GMT)

Niall Jones
Responsible Person (RP)
Kora Healthcare

Restoring Health

Kora Healthcare

Swords Business Campus,
Balheary Road, Swords,
Co. Dublin, Ireland

T + 353 (0)1 890 0406

T 1800 42 62 82

(Freephone ROI)

F + 353 (0)1 890 3016

United Kingdom

T (UK) 0845 303 8631

F (UK) 0845 303 8632

Canada

Vancouver

V6Z 2E6

E info@korahealthcare.com

www.korahealthcare.com